Zerbato Jennifer M, Serrao Erik, Lenzi Gina, Kim Baek, Ambrose Zandrea, Watkins Simon C, Engelman Alan N, Sluis-Cremer Nicolas
Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
J Virol. 2016 Aug 26;90(18):8059-73. doi: 10.1128/JVI.00553-16. Print 2016 Sep 15.
The latent HIV-1 reservoir primarily resides in resting CD4(+) T cells which are a heterogeneous population composed of both naive (TN) and memory cells. In HIV-1-infected individuals, viral DNA has been detected in both naive and memory CD4(+) T cell subsets although the frequency of HIV-1 DNA is typically higher in memory cells, particularly in the central memory (TCM) cell subset. TN and TCM cells are distinct cell populations distinguished by many phenotypic and physiological differences. In this study, we used a primary cell model of HIV-1 latency that utilizes direct infection of highly purified TN and TCM cells to address differences in the establishment and reversal of HIV-1 latency. Consistent with what is seen in vivo, we found that HIV-1 infected TN cells less efficiently than TCM cells. However, when the infected TN cells were treated with latency-reversing agents, including anti-CD3/CD28 antibodies, phorbol myristate acetate/phytohemagglutinin, and prostratin, as much (if not more) extracellular virion-associated HIV-1 RNA was produced per infected TN cell as per infected TCM cell. There were no major differences in the genomic distribution of HIV-1 integration sites between TN and TCM cells that accounted for these observed differences. We observed decay of the latent HIV-1 cells in both T cell subsets after exposure to each of the latency-reversing agents. Collectively, these data highlight significant differences in the establishment and reversal of HIV-1 latency in TN and TCM CD4(+) T cells and suggest that each subset should be independently studied in preclinical and clinical studies.
The latent HIV-1 reservoir is frequently described as residing within resting memory CD4(+) T cells. This is largely due to the consistent finding that memory CD4(+) T cells, specifically the central (TCM) and transitional memory compartments, harbor the highest levels of HIV-1 DNA in individuals on suppressive therapy. This has yielded little research into the contribution of CD4(+) naive T (TN) cells to the latent reservoir. In this study, we show that although TN cells harbor significantly lower levels of HIV-1 DNA, following latency reversal, they produced as many virions as did the TCM cells (if not more virions). This suggests that latently infected TN cells may be a major source of virus following treatment interruption or failure. These findings highlight the need for a better understanding of the establishment and reversal of HIV-1 latency in TN cells in evaluating therapeutic approaches to eliminate the latent reservoir.
潜伏的HIV-1储存库主要存在于静息CD4(+) T细胞中,这些细胞是由初始(TN)细胞和记忆细胞组成的异质群体。在HIV-1感染个体中,尽管HIV-1 DNA在记忆细胞中的频率通常更高,尤其是在中央记忆(TCM)细胞亚群中,但在初始和记忆CD4(+) T细胞亚群中均检测到了病毒DNA。TN细胞和TCM细胞是不同的细胞群体,在许多表型和生理差异上有所区别。在本研究中,我们使用了一种HIV-1潜伏的原代细胞模型,该模型利用高度纯化的TN细胞和TCM细胞的直接感染来研究HIV-1潜伏建立和逆转的差异。与体内观察结果一致,我们发现HIV-1感染TN细胞的效率低于TCM细胞。然而,当用潜伏逆转剂(包括抗CD3/CD28抗体、佛波酯/植物血凝素和原他汀)处理感染的TN细胞时,每个感染的TN细胞产生的细胞外病毒体相关HIV-1 RNA与每个感染的TCM细胞产生的一样多(甚至更多)。TN细胞和TCM细胞之间HIV-1整合位点的基因组分布没有主要差异来解释这些观察到的差异。我们观察到在暴露于每种潜伏逆转剂后,两个T细胞亚群中潜伏的HIV-1细胞均出现衰退。总体而言,这些数据突出了TN细胞和TCM CD4(+) T细胞中HIV-1潜伏建立和逆转的显著差异,并表明在临床前和临床研究中应分别对每个亚群进行研究。
潜伏的HIV-1储存库通常被描述为存在于静息记忆CD4(+) T细胞内。这主要是因为一直以来的研究发现,在接受抑制性治疗的个体中,记忆CD4(+) T细胞,特别是中央(TCM)和过渡性记忆区室,携带最高水平的HIV-1 DNA。这导致对CD4(+)初始T(TN)细胞对潜伏储存库的贡献研究较少。在本研究中,我们表明尽管TN细胞中HIV-1 DNA水平显著较低,但在潜伏逆转后,它们产生的病毒体与TCM细胞一样多(甚至更多)。这表明潜伏感染的TN细胞可能是治疗中断或失败后病毒的主要来源。这些发现凸显了在评估消除潜伏储存库的治疗方法时,更好地理解TN细胞中HIV-1潜伏建立和逆转的必要性。